BRVE Braveheart Bio, Inc. - Common Stock
NASDAQ · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Sep 8, 2026BRVE Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
BRVE Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | BRVE | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/B (MRQ) | -1.7 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | BRVE | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 13.6 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | $-2.51 | $4.40 | -157.1% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
We don't have SEC filings for this ticker yet.
Income Statement
| Metric | Trend | Q2 2026 |
|---|---|---|
| SG&A Expense | $5M | |
| Operating Expenses | $16M | |
| Operating Income | $-16M | |
| Interest Income | $889.0K | |
| Other Non-op | $894.0K | |
| Net Income | $-15M | |
| EPS (Basic) | $-2.51 | |
| EPS (Diluted) | $-2.51 | |
| Shares (Basic) | 7,401,783 | |
| Shares (Diluted) | 7,401,783 | |
| EBITDA | $-16M |
Balance Sheet
| Metric | Trend | Q2 2026 |
|---|---|---|
| Cash & Equivalents | $123M | |
| Prepaid Expense | $614.0K | |
| Current Assets | $123M | |
| PP&E (Net) | $23.0K | |
| Other Non-current Assets | $70.0K | |
| Total Assets | $127M | |
| Accounts Payable | $3M | |
| Accrued Liabilities | $6M | |
| Current Liabilities | $9M | |
| Capital Leases | $198.0K | |
| Other Non-current Liabilities | $86.0K | |
| Total Liabilities | $9M | |
| Common Stock | $1.0K | |
| Paid-in Capital | $0 | |
| Retained Earnings | $-96M | |
| Stockholders' Equity | $-96M | |
| Liabilities + Equity | $127M | |
| Shares Outstanding | 7,535,986 |
Profitability
| Metric | Trend | Q2 2026 |
|---|---|---|
| ROA | -23.6% | |
| ROE | 31.3% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 |
|---|---|---|
| Current Ratio | 13.6 | |
| Quick Ratio | 13.6 |
Per Share
| Metric | Trend | Q2 2026 |
|---|---|---|
| Book Value / Share | $-12.73 | |
| Cash / Share | $16.30 |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC, OrbiMed Capital GP IX LLC, OrbiMed Genesis GP LLC ×2 filings | Sept. 10, 2026 | 13.50% | Amendment | · | SEC |
| AH Bio Fund IV, L.P., AH Equity Partners Bio IV, L.L.C., Marc L. Andreessen, Benjamin A. Horowitz | Aug. 14, 2026 | 11.40% | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 10 insiders · 3 officers · 6 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Travis Murdoch | CEO and President | Aug. 5, 2026 A | 2,940,670 | 1 | 0 | $1,499,994 |
| James Paul Rickey | Chief Financial Officer | Aug. 5, 2026 A | 520,927 | 1 | 0 | $499,986 |
| Michele A. Anderson | Chief Development Officer | Aug. 5, 2026 A | 332,161 | 1 | 0 | $19,998 |
| Tim Lohoff | Director | Aug. 5, 2026 A | · | 0 | 0 | $0 |
| David I Malek | Director | Aug. 5, 2026 A | 533,845 | 1 | 0 | $74,988 |
| Jasper Bos | Director | Aug. 5, 2026 A | · | 0 | 0 | $0 |
| Christopher Viehbacher | Director | Aug. 5, 2026 A | 609,519 | 1 | 0 | $1,499,994 |
| David Charles Lubner | Director | Aug. 5, 2026 A | 55,555 | 1 | 0 | $999,990 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | · | Aug. 7, 2026 C | 7,420,091 | 0 | 0 | $0 |
| CHIMOVITS EREZ | · | Aug. 7, 2026 C | 273,333 | 2 | 0 | $34,920,000 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
BRVE Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
4 analysts · 2026-09-29Mean target $45.25 +112.7%
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.